<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00346372</url>
  </required_header>
  <id_info>
    <org_study_id>UCLA IRB#03-11-052</org_study_id>
    <nct_id>NCT00346372</nct_id>
  </id_info>
  <brief_title>Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <brief_summary>
    <textblock>
      During regularly scheduled appointments, Optical Coherence Tomography (OCT) is performed on
      consented subjects. The OCT is a new type of camera that takes very detailed pictures inside
      of the eye and deeper into eye tissues. Optical Coherence Tomography imaging of intraocular
      tumors may lead to improved diagnosis and monitoring of tumors within the eye.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Ocular Melanoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who meet the following Eligibility Criteria
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (18 years or older) with:

               -  choroidal nevus greater than or equal to 3.0 mm in longest basal diameter, or
                  greater than or equal to 1.25 mm in apical height or:

               -  choroidal melanoma located in the posterior pole (4mm or less from the center of
                  fovea or the border of the optic nerve head)

        Exclusion Criteria:

          -  Ocular media opacity in the tumor eye that prevents adequate functional testing or
             imaging and prior or concurrent retinal or choroidal disease in the tumor eye that
             prevents adequate functional testing or imaging
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bradley R Straatsma, MD, JD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jules Stein Eye Institute, UCLA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tara A McCannel, MD, PhD</last_name>
    <phone>(310) 206-7484</phone>
    <email>tmccannel@jsei.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brangel Rangel</last_name>
    <phone>310 794-9962</phone>
    <email>Brangel@jsei.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jules Stein Eye Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Rangel</last_name>
      <phone>310-794-9962</phone>
      <email>Brangel@jsei.ucla.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2006</study_first_submitted>
  <study_first_submitted_qc>June 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2006</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ocular Melanoma</keyword>
  <keyword>Optical Coherence Tomography</keyword>
  <keyword>Eye Tumor</keyword>
  <keyword>Choroidal Melanoma</keyword>
  <keyword>Uveal Melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

